- Prospectus filed pursuant to Rule 424(b)(3) (424B3)
January 27 2011 - 4:25PM
Edgar (US Regulatory)
|
|
|
PROSPECTUS SUPPLEMENT NO. 1
|
|
Filed Pursuant to Rule 424(b)(3)
|
|
|
(To Prospectus Dated January 18, 2011)
|
|
Registration No. 333-171639
|
16,772,209 Shares of Common Stock
This prospectus supplement supplements the information contained in our prospectus dated January 18, 2011, relating to the offer and
sale from time to time of up to 16,772,209 shares of our common stock, $0.001 par value, that may be offered for sale by certain of our current and potential future stockholders named in the prospectus under the section entitled Selling
Stockholders. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any amendments or supplements thereto.
The information appearing in the table below, as of the date hereof, supplements the information in the table appearing under the section
entitled Selling Stockholders in the prospectus, and, where the name of a selling stockholder identified in the table below also appears in the table in the prospectus, the information set forth in the table below regarding that selling
stockholder supersedes the information in the prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling Stockholder
|
|
Common Stock Owned Prior to the Offering
|
|
|
Common Stock
Being Offered
Pursuant to
this Prospectus
|
|
|
Common Stock
Owned Upon
Completion of the
Offering(2)
|
|
|
Percentage of
Common Stock
Owned
Upon
Completion of the
Offering(2)
|
|
|
Shares
Outstanding
|
|
|
Milestone
Shares(6)
|
|
|
|
|
Bio-Star Private Equity Fund, LLC
|
|
|
|
|
|
|
147,025
|
|
|
|
147,025
|
|
|
|
|
|
|
|
*
|
|
Bio-Star Private Equity Fund FP, LLC
|
|
|
|
|
|
|
58,884
|
|
|
|
58,884
|
|
|
|
|
|
|
|
*
|
|
Achim Max Holmes
|
|
|
659
|
|
|
|
|
|
|
|
659
|
|
|
|
|
|
|
|
*
|
|
Ajay Bhalla
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Ajit S. Chauhan
|
|
|
346
|
|
|
|
|
|
|
|
346
|
|
|
|
|
|
|
|
*
|
|
AJWC Ltd. (William Wu)
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Anderieck Holdings, LLC
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Anna Junia Doan Trust dtd 10/14/03
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Anne Arbetter Fishell Trust
|
|
|
1,040
|
|
|
|
|
|
|
|
1,040
|
|
|
|
|
|
|
|
*
|
|
Anthony J. DAnna
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Arthur P. Dore
|
|
|
3,468
|
|
|
|
|
|
|
|
3,468
|
|
|
|
|
|
|
|
*
|
|
Bruce Edward Roberts
|
|
|
173
|
|
|
|
|
|
|
|
173
|
|
|
|
|
|
|
|
*
|
|
Christopher G. Miller
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Daniel M. Honigman Trust
|
|
|
694
|
|
|
|
|
|
|
|
694
|
|
|
|
|
|
|
|
*
|
|
David D. MacDonald
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
David R. Johnston
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
David V. Johnson
|
|
|
1,661
|
|
|
|
|
|
|
|
1,661
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling Stockholder
|
|
Common Stock Owned Prior to the Offering
|
|
|
Common Stock
Being Offered
Pursuant to
this Prospectus
|
|
|
Common Stock
Owned Upon
Completion of the
Offering(2)
|
|
|
Percentage of
Common Stock
Owned
Upon
Completion of the
Offering(2)
|
|
|
Shares
Outstanding
|
|
|
Milestone
Shares(6)
|
|
|
|
|
Dennis K. and Alexis Branoff
|
|
|
1,040
|
|
|
|
|
|
|
|
1,040
|
|
|
|
|
|
|
|
*
|
|
FrontPoint Healthcare
|
|
|
9,883
|
|
|
|
|
|
|
|
9,883
|
|
|
|
|
|
|
|
*
|
|
FrontPoint Healthcare Horizons Fund
|
|
|
3,294
|
|
|
|
|
|
|
|
3,294
|
|
|
|
|
|
|
|
*
|
|
FrontPoint Healthcare Horizons Fund, L.P.
|
|
|
58,769
|
|
|
|
|
|
|
|
58,769
|
|
|
|
|
|
|
|
*
|
|
Gary Emede
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Gilbert S. Omenn, M.D.
|
|
|
700
|
|
|
|
|
|
|
|
700
|
|
|
|
|
|
|
|
*
|
|
Glenn Mierendorf
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Gregg Stone
|
|
|
694
|
|
|
|
|
|
|
|
694
|
|
|
|
|
|
|
|
*
|
|
J. Douglas Turnbull Trust
|
|
|
420
|
|
|
|
|
|
|
|
420
|
|
|
|
|
|
|
|
*
|
|
James Jesko, M.D.
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Jason Bonadio
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Jennifer Burdette
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Jim Goldstein
|
|
|
1,050
|
|
|
|
|
|
|
|
1,050
|
|
|
|
|
|
|
|
*
|
|
Joseph F. Skowron III
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Joseph M. Cohen
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Kim Pavlik
|
|
|
1,040
|
|
|
|
|
|
|
|
1,040
|
|
|
|
|
|
|
|
*
|
|
Larry L. Preston
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Louis Cannon, M.D.
|
|
|
1,036
|
|
|
|
|
|
|
|
1,036
|
|
|
|
|
|
|
|
*
|
|
Marc Levin Revocable Trust
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Mark Flegenheimer
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Medley Larkin, M.D.
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Michael Beirlein, InterVivos Trust
|
|
|
3,468
|
|
|
|
|
|
|
|
3,468
|
|
|
|
|
|
|
|
*
|
|
Michael D. Young, Sr.
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Mike Henson
|
|
|
692
|
|
|
|
|
|
|
|
692
|
|
|
|
|
|
|
|
*
|
|
Morrison Stevens
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Nantucket Venture Partners, LLC
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Nest Egg Holdings, LLC
|
|
|
2,774
|
|
|
|
|
|
|
|
2,774
|
|
|
|
|
|
|
|
*
|
|
Noel Rahn
|
|
|
694
|
|
|
|
|
|
|
|
694
|
|
|
|
|
|
|
|
*
|
|
North Sound Private Strategies, LLC
|
|
|
19,766
|
|
|
|
|
|
|
|
19,766
|
|
|
|
|
|
|
|
*
|
|
Patrick Gallagher
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Paul Capital Partners VIII Holdings
|
|
|
5,895
|
|
|
|
|
|
|
|
5,895
|
|
|
|
|
|
|
|
*
|
|
Paul Capital Partners IX, L.P.
|
|
|
7,976
|
|
|
|
|
|
|
|
7,976
|
|
|
|
|
|
|
|
*
|
|
Raymond Hausbeck
|
|
|
694
|
|
|
|
|
|
|
|
694
|
|
|
|
|
|
|
|
*
|
|
Renee Masi
|
|
|
692
|
|
|
|
|
|
|
|
692
|
|
|
|
|
|
|
|
*
|
|
Richard J. Garber Trust
|
|
|
3,468
|
|
|
|
|
|
|
|
3,468
|
|
|
|
|
|
|
|
*
|
|
Richard Resler
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Robert Safian, M.D.
|
|
|
735
|
|
|
|
|
|
|
|
735
|
|
|
|
|
|
|
|
*
|
|
Robert Weltman
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling Stockholder
|
|
Common Stock Owned Prior to the Offering
|
|
|
Common Stock
Being Offered
Pursuant to
this Prospectus
|
|
|
Common Stock
Owned Upon
Completion of the
Offering(2)
|
|
|
Percentage of
Common Stock
Owned
Upon
Completion of the
Offering(2)
|
|
|
Shares
Outstanding
|
|
|
Milestone
Shares(6)
|
|
|
|
|
Roger Kahn
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Ronald P. Caputo
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
RR Bio Investments
|
|
|
3,537
|
|
|
|
|
|
|
|
3,537
|
|
|
|
|
|
|
|
*
|
|
Ryan Bierlein
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
SSP Investments
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
Steve Kocks
|
|
|
347
|
|
|
|
|
|
|
|
347
|
|
|
|
|
|
|
|
*
|
|
Steven C. Ajluni, M.D.
|
|
|
1,206
|
|
|
|
|
|
|
|
1,206
|
|
|
|
|
|
|
|
*
|
|
Steven J. Yakubov
|
|
|
728
|
|
|
|
|
|
|
|
728
|
|
|
|
|
|
|
|
*
|
|
Steven L. Almany, M.D.
|
|
|
1,950
|
|
|
|
|
|
|
|
1,950
|
|
|
|
|
|
|
|
*
|
|
The Abernathy Group Growth Trust
|
|
|
5,202
|
|
|
|
|
|
|
|
5,202
|
|
|
|
|
|
|
|
*
|
|
The Herbert H. & Grace A. Dow Foundation
|
|
|
13,871
|
|
|
|
|
|
|
|
13,871
|
|
|
|
|
|
|
|
*
|
|
Thomas M. Perkins
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
Tim A. Fischell
|
|
|
1,040
|
|
|
|
|
|
|
|
1,040
|
|
|
|
|
|
|
|
*
|
|
Trout Partners, LLC
|
|
|
1,977
|
|
|
|
|
|
|
|
1,977
|
|
|
|
|
|
|
|
*
|
|
WHI Morula Fund, LLC
|
|
|
2,081
|
|
|
|
|
|
|
|
2,081
|
|
|
|
|
|
|
|
*
|
|
William Devlin
|
|
|
1,085
|
|
|
|
|
|
|
|
1,085
|
|
|
|
|
|
|
|
*
|
|
William J. Mulders, Jr.
|
|
|
694
|
|
|
|
|
|
|
|
694
|
|
|
|
|
|
|
|
*
|
|
Investing in
our common stock involves a high degree of risk. You should review the section entitled Risk Factors beginning on page 2 of the prospectus to read about the risks you should consider carefully before buying shares of our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
determined if the prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus supplement is January 27, 2011.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From May 2024 to Jun 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2023 to Jun 2024